Assessment of the use of long-acting insulin in management of diabetic ketoacidosis in pediatric patients: a randomized controlled trial
- PMID: 39778214
- PMCID: PMC12061761
- DOI: 10.6065/apem.2448086.043
Assessment of the use of long-acting insulin in management of diabetic ketoacidosis in pediatric patients: a randomized controlled trial
Abstract
Purpose: We evaluated the effectiveness of early start of long-acting insulin during management of diabetic ketoacidosis (DKA) in pediatric patients.
Methods: Patients with DKA were randomly assigned to receive either a traditional DKA management protocol or concurrent administration of subcutaneous (SC) long-acting insulin alongside intravenous insulin during DKA treatment. The primary outcomes were duration of insulin infusion and adverse effects of the intervention, mainly hypoglycemia and hypokalemia.
Results: For this study, 100 pediatric patients with DKA were enrolled, 50 in each group (group I received the conventional DKA management and group II received conventional DKA management plus SC long-acting insulin once daily). Patients in group II showed a significant reduction in both duration and dose of insulin infusion compared to group I, with a median (interquartile range) of 68.5 hours (45.00-88.25 hours) versus 72 hours (70.25-95.5 hours) (P=0.0001) and an insulin dose of 3.48±1.00 units/kg versus 4.04±1.17 units/kg (P=0.016), respectively. Concurrent administration of SC long-acting insulin with intravenous insulin during DKA treatment was associated with a decreased risk of hypoglycemia (number of hypoglycemia events: group I, 22 events; group II, 12 events, P=0.029), with no increased risk of hypokalemia compared to the control group (number of hypokalemia events: group I, 12 events; group II, 19 events, P=0.147).
Conclusion: The current study showed that coadministration of SC long-acting insulin in addition to the usual insulin infusion during DKA management in the pediatric population can lead to a shorter duration of insulin infusion. In addition, this approach is not associated with increased risk of hypoglycemia or hypokalemia. Moreover, coadministration of long-acting insulin may be associated with a decreased incidence of hypoglycemia.
Keywords: Child; Diabetic ketoacidosis; Insulin; Long-acting.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Similar articles
-
Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial.Diabetes Obes Metab. 2023 Mar;25(3):815-822. doi: 10.1111/dom.14929. Epub 2022 Dec 20. Diabetes Obes Metab. 2023. PMID: 36479786 Clinical Trial.
-
Early Versus Late Administration of Long-Acting Insulin in Adult Diabetic Ketoacidosis.Ann Pharmacother. 2025 Jun;59(6):549-553. doi: 10.1177/10600280241278371. Epub 2024 Sep 9. Ann Pharmacother. 2025. PMID: 39250171
-
Retrospective Comparison of Early Versus Late Initiation of Long-Acting Insulin in Critically Ill Pediatric Patients in Diabetic Ketoacidosis.J Pediatr Pharmacol Ther. 2024 Dec;29(6):614-623. doi: 10.5863/1551-6776-29.6.614. Epub 2024 Dec 9. J Pediatr Pharmacol Ther. 2024. PMID: 39659852 Free PMC article.
-
Subcutaneous fast-acting insulin analogues ± long-acting insulin vs IV insulin infusion in DKA: updated meta-analysis of randomised trials.Endocrine. 2025 Mar;87(3):920-932. doi: 10.1007/s12020-024-04071-0. Epub 2024 Oct 16. Endocrine. 2025. PMID: 39414709
-
Basal insulin for the management of diabetic ketoacidosis.Eur J Intern Med. 2018 Jan;47:14-16. doi: 10.1016/j.ejim.2017.08.025. Epub 2017 Aug 31. Eur J Intern Med. 2018. PMID: 28864157 Review.
References
-
- Glaser N, Fritsch M, Priyambada L, Rewers A, Cherubini V, Estrada S, et al. ISPAD clinical practice consensus guidelines 2022: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes. 2022;23:835–56. - PubMed
LinkOut - more resources
Full Text Sources